Agree on this one. I would really like to see PR replaced as Chair of the Board, whilst I am very much a believer in the product, there is starting to be a mounting number of governance issues, e.g. missing timeframes, confusing comments regarding overall timelines (R&D Conference). I think he is a great CEO and often says the right things, but actions are not always following. An experienced bio-tech Chair would be very good for the company in the long run, IMO.
Ann: IND QUESTIONS RECEIVED FROM US FDA, page-323
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |